Hera Biotech’s Post

The predictive and diagnostic tools created by Class 10 address some of the most prevalent problems for everyday patients. Today, we are excited to introduce Healthplus.ai and Hera Biotech. Healthplus.ai is enabling proactive surgery care through personalized complication predictions. Healthplus.ai's CE IIa certified solution, PERISCOPE®, is an AI-based decision support tool that highly-accurately predicts infection risks using existing EHR data, facilitating early intervention, eliminating unnecessary hospital stays, and reducing readmissions. Healthplus.ai uses real-time data along with validated & locally recalibrated machine learning algorithms to integrate with the existing workflow to aid clinical staff, delivering proactive and individualized care. Hera Biotech offers the world’s first non-surgical test for endometriosis, the number one cause of female infertility. Hera's test, MetriDx™, provides definitive diagnosis and staging of endometriosis through tissue-based analysis. MetriDx™ measures the expression patterns of an endometriosis-specific gene panel. Hera Biotech's patent-protected panel is heavily based on the expression profiles of a gene set implicated in a number of other invasive processes. Hera Biotech primarily serves the OB/GYN and fertility solutions markets with its innovative diagnostic tool. #CSaccelerator #healthinnovate #healthaccelerator #HIT #healthdisruptors #CSAclass10

https://lnkd.in/dJ6SibHe Finally out our latest SRMA on Computer-aided diagnosis for leaving colorectal polyps in situ, published in the prestigious Annals Internal Medicine! * Ten studies, including 3620 patients * Pooled sensitivity with CADx alone 87.3% (95% CI, 79.2% to 92.5%) and specificity 88.9% (CI, 81.7% to 93.5%) in predicting neoplastic change. * No difference before vs after CAD in the proportion of polyps predicted to be nonneoplastic that would avoid removal (RR 1.06, CI, 0.96 to 1.17) nor in the proportion of neoplastic polyps that would be erroneously left in situ (RR, 0.95, 0.69 to 1.33). Therefore, CAD provided no incremental benefit or harm in the management of small rectosigmoid polyps during colonoscopy. Cesare Hassan, Masashi Misawa Tommy Rizkala Yuichi Mori Shahnaz Sultan Giulio Antonelli Marco Spadaccini Britt B S L Houwen Emanuele Rondonotti Harsh Patel Kareem Khalaf James Weiquan Li Gloria M Fernandez Pradeep Bhandari Evelien Dekker Seth Gross Tyler Berzin Per Olav Vandvik Loredana Correale Shin-Ei Kudo Prateek Sharma Douglas Rex Alessandro Repici Farid Foroutan

terrific discussion yesterday led by the ADEA oral diagnosis community [thanks Sahar Mirfarsi, DDS, FICD for organizing the virtual session] the discussion focused on challenges and opportunities incorporating orofacial pain into the #curriculum and addressing #accreditation standards; reflecting on the discussion, I see the topic as one of five pillars in practical #oralmedicine instruction: management of oral ulcerative, immune, and inflammatory disease the impact of systemic disease and the role of #medicine in oral health management soft and hard tissue #radiology and #pathology, biopsy and tissue submission, and communication with the laboratory oral oncology, tumor board, and post-surgical and post-oncologic care in #dentistry orofacial pain, musculoskeletal disorders, and the role of healthcare practitioners in diagnosis and referral

https://lnkd.in/gRxU3Wg6 Mr.Naresh Ahuja, Founder & CEO of SMS Scientific Products Pvt Ltd Spoke exclusively with Modern Medi Health, A Healthcare Media Network (Empowering Patient Education: SMS's Innovative Consultation Tool Transforms Doctor-Patient Communication) Imagine a scenario where a urologist is consulting with a patient about prostate health. Traditionally, explaining complex prostate conditions like benign prostatic hyperplasia (BPH) or prostate cancer relied heavily on verbal descriptions, anatomical models, and medical jargon. This often led to confusion and limited patient understanding.   With SMS's prostate consultation tool, the urologist now has access to a comprehensive set of illustration boards specifically designed for prostate health discussions. These boards feature detailed illustrations of the prostate gland, urinary tract, and common prostate conditions. For instance, one board depicts the normal anatomy of the prostate, highlighting key structures and functions. Naresh Ahuja SMS Scientific Products PVT.LTD

Adapted from the Article:Artificial intelligence in gastroenterology: A state-of-the-art review Artificial intelligence (AI) clinical applications in gastroenterology and hepatology, which heavily relies on imaging, have dramatically expanded in the last 20 years. These applications include the detection of lesions, identification of premalignant or malignant lesions, development of objective scoring systems for risk stratification, predicting disease prognosis or treatment response, or evaluation of metrics such as bowel preparation score or quality of endoscopic examination

The role of accurate and reliable laboratory diagnostic technique is paramount for early and veracious detection of diseases. In our new piece of #published work, we investigated the #accuracy of disregulated long noncoding RNAs (#lncRNAs) and circular RNAs (#circRNAs) in diagnosing Inflammatory Bowel Diseases (#IBD) overcoming the nonspecific, conventional and invasive diagnosis techniques including clinical symptoms, radiology, endoscopy and repeated biopsy examinations. Accordingly, lncRNAs exhibit #high diagnostic accuracy (pooled #sensitivity 0.94 (95% CI: 0.87-0.97), #specificity 0.99 (95% CI: 0.89-1.00), and #AUC 0.99 (95% CI: 0.97-0.99) along with #PLR, #NLR, and #DOR values of 64.25 (95% CI: 7.39-558.66), 0.06 (95% CI: 0.03-0.13), and 1055.25 (95% CI: 70.61-15770.77), respectively) in distinguishing patients with IBD from healthy controls signifying their possible use as #potential #biomarkers, while circRNAs showed moderate diagnostic accuracy. Our investigation also point out the performance of serum #lncRNA H19 as a better and more suitable diagnostic marker for IBD with heightened ability for both #exclusion and #confirmation of #IBD. #Research, #New #Publication, #Laboratory diagnosis, #Diagnostic markers, #lncRNA, #circRNA, #IBD, #Meta-analysis

term male neonate with MAS,HIE,pulmonary hypertension,& Respiratory failure (OI 45) POCLUS diagnostic criteria for MAS(finding is heterogeneous bilateral lung pathology :- 1- Consolidation & airbronchogram 2-Abnormal pleural line 3-B line 4-Atelectasis 5-Pleural effusion 6-lung pulse Note from 1 to 4 present in All cases of MAS

The global shortage of pathologists is reaching critical levels, with New Zealand facing significant impacts. A recent DarkIntelligence report reveals that New Zealanders are now waiting up to eight weeks for melanoma diagnoses, highlighting the severity of the crisis. This isn't just a local issue; it's a wake-up call for the global healthcare community. The transition to digital pathology isn't just inevitable, it's imperative. Embracing digital innovation in pathology can lead to more timely diagnoses and better patient outcomes worldwide. 👉 https://lnkd.in/eDT47zkQ #DigitalPathology #HealthcareInnovation #PatientCare

Ophthopedia Update:Screening of Glaucoma: Consensus and Directions: Purpose: Glaucoma is a leading public health concern globally. This summary discusses barriers to glaucoma screening and novel strategies for a cost-effective glaucoma screening. Methods/Results: We discuss barriers to glaucoma screening and recent advancements in glaucoma detection and care, including targeted screening approach as well as telemedicine, genetic testing, and artificial intelligence (AI). A major barrier to glaucoma screening is the cost-effectiveness of case finding resulting from the low prevalence of the disease and the complexity of the diagnosis. Targeted–screening, as well as multi-level screening, can reduce the false positive rate and increase the cost-effectiveness of the program. Telemedicine, availability of genetic testing and polygenic risk scores, and AI provide the opportunity for novel glaucoma screening programs in primary care, portable, and home-based settings and will be helpful for lowering the costs, identifying patients in need of urgent treatment and enabling timely diagnosis and early intervention. Conclusions: Screening of glaucoma is challenging and changing. Recent advancements in digital technology and genetics have led to the development of tools that are promising for novel screening methodologies. Clinical trials are needed to demonstrate the long-term effect of targeted screening on the burden of glaucoma worldwide. #Ophthalmology #Eye #Ophthotwitter

As we discussed throughout this series, #pharmacogenetics has major potential benefits for both patients and #healthcare systems, including: 💊 Preventing up to 30% of adverse drug reactions 🏥 Reducing length of hospital stays 💸 Reducing cost of treatment for healthcare providers 👂 This is why we developed the Genedrive MT-RNR1 ID Kit: the WORLD’S FIRST #pointofcare genetic test used to influence neonatal management in an acute setting and reduce the risk of antibiotic induced #hearingloss 👨⚕️ The m.1555A>G variant of the MT-RNR1 gene results in a high risk of an adverse drug reaction when exposed to aminoglycoside #antibiotics that causes antibiotic induced hearing loss. Treating the damage requires dual cochlear implant surgery and lifelong recurring hospital visits to audiologists, at considerable cost to healthcare providers. 👍 With the Genedrive MT-RNR1 ID Kit, healthcare professionals, including #nurses can perform a rapid pharmacogenetic test for MT-RNR1 variant status to identify high-risk individuals. This way, we can reduce the risk of antibiotic induced hearing loss, without disrupting the normal high standards of emergency healthcare. 🔗 To learn more, listen to the This Week in Hearing Health Matters podcast by our Chief Scientific Officer Dr. Gino Miele, with Dr John H McDermott and Dr. Nicola Booth from Manchester University NHS Foundation Trust here: https://lnkd.in/gh9vVrpd #GDR #POCT #pharmacogenomics #medtech #genetics #innovation #personalizedmedicine #pgxmovement #MTRNR1